Correlation Between Editas Medicine and Milestone Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Editas Medicine and Milestone Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Editas Medicine and Milestone Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Editas Medicine and Milestone Pharmaceuticals, you can compare the effects of market volatilities on Editas Medicine and Milestone Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Editas Medicine with a short position of Milestone Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Editas Medicine and Milestone Pharmaceuticals.

Diversification Opportunities for Editas Medicine and Milestone Pharmaceuticals

-0.63

Correlation Coefficient

Editas Medicine  Milestone Pharmaceuticals

Excellent diversification

The 3 months correlation between Editas and Milestone is -0.63. Overlapping area represents the amount of risk that can be diversified away by holding Editas Medicine and Milestone Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Milestone Pharmaceuticals and Editas Medicine is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Editas Medicine are associated (or correlated) with Milestone Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Milestone Pharmaceuticals has no effect on the direction of Editas Medicine i.e., Editas Medicine and Milestone Pharmaceuticals go up and down completely randomly.

Pair Corralation between Editas Medicine and Milestone Pharmaceuticals

Given the investment horizon of 90 days Editas Medicine is expected to under-perform the Milestone Pharmaceuticals. In addition to that, Editas Medicine is 1.39 times more volatile than Milestone Pharmaceuticals. It trades about -0.15 of its total potential returns per unit of risk. Milestone Pharmaceuticals is currently generating about 0.2 per unit of volatility. If you would invest  139.00  in Milestone Pharmaceuticals on September 3, 2024 and sell it today you would earn a total of  60.00  from holding Milestone Pharmaceuticals or generate 43.17% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Editas Medicine  vs.  Milestone Pharmaceuticals

Editas Medicine

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Editas Medicine has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Milestone Pharmaceuticals

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Milestone Pharmaceuticals are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Milestone Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Editas Medicine and Milestone Pharmaceuticals

The main advantage of trading using opposite Editas Medicine and Milestone Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Editas Medicine position performs unexpectedly, Milestone Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Milestone Pharmaceuticals will offset losses from the drop in Milestone Pharmaceuticals' long position.

The idea behind Editas Medicine and Milestone Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.